Phase 2 Randomized, Controlled, Human Influenza A (H1N1) Challenge Study Following Administration of an Oral H1N1 HA Adenoviral-Vector Based Seasonal Influenza Vaccine and dsRNA Adjuvant to Healthy Adult Volunteers

Trial Profile

Phase 2 Randomized, Controlled, Human Influenza A (H1N1) Challenge Study Following Administration of an Oral H1N1 HA Adenoviral-Vector Based Seasonal Influenza Vaccine and dsRNA Adjuvant to Healthy Adult Volunteers

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs VXA-A1-1 (Primary) ; Influenza virus vaccine
  • Indications Influenza A virus H1N1 subtype
  • Focus Therapeutic Use
  • Acronyms Challenge
  • Sponsors Vaxart
  • Most Recent Events

    • 02 Apr 2018 According to a Vaxart media release, complete results from this study will be presented at the World Vaccine Congress (WVC) 2018.
    • 04 Mar 2018 Results assessing efficacy and immunogenicity presented at the 18th International Congress on Infectious Diseases
    • 31 Jan 2018 Results published in the Vaxart Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top